Raras
Buscar doenças, sintomas, genes...
Neuroblastoma
ORPHA:635CID-10 · C74.9CID-11 · 2A00.11DOENÇA RARA

Neuroblastoma (NB) é o câncer sólido mais comum em crianças, que se desenvolve fora do crânio. É um tipo de câncer infantil agressivo que surge a partir de células especiais chamadas crista neural, que fazem parte do sistema nervoso simpático.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Neuroblastoma (NB) é o câncer sólido mais comum em crianças, que se desenvolve fora do crânio. É um tipo de câncer infantil agressivo que surge a partir de células especiais chamadas crista neural, que fazem parte do sistema nervoso simpático.

Pesquisas ativas
36 ensaios
760 total registrados no ClinicalTrials.gov
Publicações científicas
44.041 artigos
Último publicado: 2026

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
11.0
Europe
Início
Adolescent
+ antenatal, childhood, infancy, neonatal
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C74.9
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
6 sintomas
🫘
Rins
3 sintomas
🫃
Digestivo
3 sintomas
🧠
Neurológico
2 sintomas
🦴
Ossos e articulações
2 sintomas
📏
Crescimento
1 sintomas

+ 13 sintomas em outras categorias

Características mais comuns

90%prev.
Neuroblastoma
Muito frequente (99-80%)
90%prev.
Catecolaminas urinárias elevadas
Muito frequente (99-80%)
90%prev.
Neoplasia do sistema nervoso
Muito frequente (99-80%)
55%prev.
Perda de peso
Frequente (79-30%)
55%prev.
Nível elevado de catecolamina circulante
Frequente (79-30%)
55%prev.
Massa abdominal
Frequente (79-30%)
34sintomas
Muito frequente (3)
Frequente (10)
Ocasional (16)
Muito raro (5)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 34 características clínicas mais associadas, ordenadas por frequência.

Neuroblastoma
Muito frequente (99-80%)90%
Catecolaminas urinárias elevadasElevated urinary catecholamines
Muito frequente (99-80%)90%
Neoplasia do sistema nervosoNeoplasm of the nervous system
Muito frequente (99-80%)90%
Perda de pesoWeight loss
Frequente (79-30%)55%
Nível elevado de catecolamina circulanteElevated circulating catecholamine level
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico44.041PubMed
Últimos 10 anos200publicações
Pico2026196 papers
Linha do tempo
2026Hoje · 2026🧪 1987Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

6 genes identificados com associação a esta condição. Padrão de herança: Not applicable.

HACE1E3 ubiquitin-protein ligase HACE1Major susceptibility factor inTolerante
FUNÇÃO

E3 ubiquitin-protein ligase involved in Golgi membrane fusion and regulation of small GTPases (PubMed:15254018, PubMed:21988917, PubMed:22036506, PubMed:37537642, PubMed:38332367). Acts as a regulator of Golgi membrane dynamics during the cell cycle: recruited to Golgi membrane by Rab proteins and regulates postmitotic Golgi membrane fusion (PubMed:21988917). Acts by mediating ubiquitination during mitotic Golgi disassembly, ubiquitination serving as a signal for Golgi reassembly later, after ce

LOCALIZAÇÃO

Golgi apparatus, Golgi stack membraneCytoplasmEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Antigen processing: Ubiquitination & Proteasome degradation
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
24.8 TPM
Cerebelo
23.5 TPM
Cervix Ectocervix
16.4 TPM
Nervo tibial
15.5 TPM
Cervix Endocervix
14.8 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
spastic paraplegia-severe developmental delay-epilepsy syndromeneuroblastoma
HGNC:21033UniProt:Q8IYU2
LIN28BProtein lin-28 homolog BMajor susceptibility factor inAltamente restrito
FUNÇÃO

Suppressor of microRNA (miRNA) biogenesis, including that of let-7 and possibly of miR107, miR-143 and miR-200c. Binds primary let-7 transcripts (pri-let-7), including pri-let-7g and pri-let-7a-1, and sequester them in the nucleolus, away from the microprocessor complex, hence preventing their processing into mature miRNA (PubMed:22118463). Does not act on pri-miR21 (PubMed:22118463). The repression of let-7 expression is required for normal development and contributes to maintain the pluripoten

LOCALIZAÇÃO

NucleusNucleus, nucleolusCytoplasm

EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
4.6 TPM
Pituitária
0.4 TPM
Brain Frontal Cortex BA9
0.4 TPM
Hipotálamo
0.3 TPM
Córtex cerebral
0.3 TPM
OUTRAS DOENÇAS (1)
neuroblastoma
HGNC:32207UniProt:Q6ZN17
MYCNN-myc proto-oncogene proteinBiomarker tested inAltamente restrito
FUNÇÃO

Positively regulates the transcription of MYCNOS in neuroblastoma cells

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (4)
Regulation of CDH1 mRNA translation by microRNAsRegulation of PD-L1(CD274) transcriptionSignaling by ALKTGFBR3 expression
EXPRESSÃO TECIDUAL(Tecido-específico)
Nervo tibial
7.5 TPM
Testículo
6.8 TPM
Brain Spinal cord cervical c-1
5.6 TPM
Tireoide
5.0 TPM
Glândula salivar
4.8 TPM
OUTRAS DOENÇAS (5)
megalencephaly-polydactyly syndromeFeingold syndrome type 1hereditary retinoblastomaneuroblastoma
HGNC:7559UniProt:P04198
PHOX2BPaired mesoderm homeobox protein 2BMajor susceptibility factor inAltamente restrito
FUNÇÃO

Involved in the development of several major noradrenergic neuron populations, including the locus coeruleus. Transcription factor which could determine a neurotransmitter phenotype in vertebrates. Enhances second-messenger-mediated activation of the dopamine beta-hydrolase and c-fos promoters, and of several enhancers including cAMP-response element and serum-response element

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Central hypoventilation syndrome, congenital, 1

An autosomal dominant form of congenital central hypoventilation syndrome, a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
4.1 TPM
Cólon transverso
1.5 TPM
Intestino delgado
0.8 TPM
Esôfago - Muscular
0.5 TPM
Esôfago - Junção
0.4 TPM
OUTRAS DOENÇAS (5)
neuroblastoma, susceptibility to, 2central hypoventilation syndrome, congenital, 1, with or without Hirschsprung diseaseHirschsprung disease-ganglioneuroblastoma syndromeneuroblastoma
HGNC:9143UniProt:Q99453
LMO1Rhombotin-1Major susceptibility factor inTolerante
FUNÇÃO

May be involved in gene regulation within neural lineage cells potentially by direct DNA binding or by binding to other transcription factors

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
RUNX1 regulates transcription of genes involved in differentiation of HSCs
EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Not Sun Exposed Suprapubic
8.6 TPM
Skin Sun Exposed Lower leg
6.1 TPM
Músculo esquelético
4.8 TPM
Testículo
4.3 TPM
Hipotálamo
3.4 TPM
OUTRAS DOENÇAS (1)
neuroblastoma
HGNC:6641UniProt:P25800
ALKALK tyrosine kinase receptorMajor susceptibility factor inRestrito
FUNÇÃO

Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system (PubMed:11121404, PubMed:11387242, PubMed:16317043, PubMed:17274988, PubMed:30061385, PubMed:34646012, PubMed:34819673). Also acts as a key thinness protein involved in the resistance to weight gain: in hypothalamic neurons, controls energy expenditure acting as a nega

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Signaling by ALKMDK and PTN in ALK signaling
OUTRAS DOENÇAS (9)
large congenital melanocytic nevusneuroblastomaganglioneuroblastomadifferentiated thyroid carcinoma
HGNC:427UniProt:Q9UM73

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 Doxorubicin Hydrochloride (DOXORUBICIN HYDROCHLORIDE)
💊 CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

5,074 variantes patogênicas registradas no ClinVar.

🧬 ALK: NM_004304.5(ALK):c.793G>A (p.Glu265Lys) ()
🧬 ALK: NM_004304.5(ALK):c.1546+18C>T ()
🧬 ALK: NM_004304.5(ALK):c.2752_2754del (p.Arg918del) ()
🧬 ALK: NM_004304.5(ALK):c.1912+10C>A ()
🧬 ALK: NM_004304.5(ALK):c.595G>C (p.Gly199Arg) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 5,293 variantes classificadas pelo ClinVar.

2911
2382
VUS (55.0%)
Benigna (45.0%)
VARIANTES MAIS SIGNIFICATIVAS
KIF1B: NM_001365951.3(KIF1B):c.3130-3C>G [Uncertain significance]
KIF1B: NM_001365951.3(KIF1B):c.2655C>G (p.His885Gln) [Uncertain significance]
KIF1B: NM_001365951.3(KIF1B):c.2115+6901C>T [Uncertain significance]
ALK: NM_004304.5(ALK):c.793G>A (p.Glu265Lys) [Uncertain significance]
ALK: NM_004304.5(ALK):c.2752_2754del (p.Arg918del) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 31
2Fase 211
1Fase 14
·Pré-clínico4
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Neuroblastoma

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

20 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT01109394 · Comprehensive Omics Analysis of Pediatric and Adult Solid Tu…Recrutando
NCT04897321 · B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell T…Recrutando
PHASE1
NCT06995872 · Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Te…Recrutando
PHASE1
NCT06721689 · PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tu…Recrutando
PHASE1, PHASE2
NCT06638931 · Agnostic Therapy in Rare Solid TumorsRecrutando
PHASE2
NCT04308330 · Vorinostat in Combination With Chemotherapy in Relapsed/Refr…Recrutando
PHASE1
NCT06607692 · Study in Children and Adolescents of 177Lu-DOTATATE (Lutathe…Recrutando
PHASE1, PHASE2
NCT06172296 · Dinutuximab With Chemotherapy, Surgery and Stem Cell Transpl…Recrutando
PHASE3
NCT01005654 · Prospective Comprehensive Molecular Analysis of Endocrine Ne…Recrutando
NCT06465199 · Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tum…Recrutando
PHASE1, PHASE2
NCT06395103 · Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Ad…Recrutando
PHASE1, PHASE2
NCT04901702 · Study of Onivyde With Talazoparib or Temozolomide in Childre…Recrutando
PHASE1, PHASE2
NCT06541262 · Silmitasertib (CX-4945) in Combination With Chemotherapy for…Recrutando
PHASE1, PHASE2
NCT06176989 · Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Bas…Recrutando
PHASE2
NCT04755205 · A Natural History Study of Children and Adults With Olfactor…Recrutando
NCT07516678 · Serial ctDNA and Molecular Residual Disease Monitoring in Ne…Recrutando
NCT06057948 · A Study of a Vaccine in Combination With Beta-glucan in Peop…Recrutando
PHASE2
NCT00107289 · Iodine I 131 Metaiodobenzylguanidine in Treating Patients Wi…Recrutando
PHASE2
NCT07502287 · Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or…Recrutando
PHASE1, PHASE2
NCT03721068 · Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 …Recrutando
PHASE1

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

💬Melhor nível de evidência: Opinião
Timeline de publicações
15.778 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 15.778

#1

Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia.

The Turkish journal of pediatrics2026 Feb 27

Este estudo destaca a Síndrome Opsoclonus-Mioclonus-Ataxia (OMAS) associada ao neuroblastoma em crianças, uma condição neurológica rara, imunomediada e frequentemente subestimada. Para pais e médicos, é vital reconhecer que a ataxia é o sintoma inicial mais comum, frequentemente acompanhada de distúrbios comportamentais e do sono, e que o opsoclonus (movimentos oculares rápidos) pode ser mal interpretado. A detecção precoce da OMAS em crianças pequenas (18-36 meses) é crucial para o diagnóstico oportuno do neuroblastoma subjacente e para um manejo adequado.

🇧🇷 traduzido
#2

LMO1 expression in neuroblastoma cells reprograms tumor-associated macrophages to promote metastasis.

iScience2026 Mar 20

O neuroblastoma é um câncer pediátrico agressivo e frequentemente metastático. Este estudo revela que a proteína LMO1, expressa em células de neuroblastoma, reprograma macrófagos (células imunes) para que estes auxiliem na metástase. Ao induzir as células tumorais a secretar fatores que ativam os macrófagos, LMO1 promove a degradação de tecidos e a migração das células cancerígenas, oferecendo um alvo promissor para novas terapias que visem impedir a disseminação da doença.

🇧🇷 traduzido
#3

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience.

Pediatric blood &amp; cancer2026 Mar 16

Este estudo nacional britânico confirma a eficácia e tolerabilidade do tratamento BIT (bevacizumabe, irinotecano e temozolomida) para neuroblastoma recidivante ou refratário, uma condição com prognóstico geralmente desfavorável. A terapia demonstrou uma taxa de resposta objetiva de 40,6%, com melhora significativa na sobrevida livre de progressão e sobrevida global, especialmente em pacientes com doença refratária. Embora os efeitos colaterais comuns incluam anemia, febre neutropênica e diarreia, o tratamento foi geralmente bem tolerado, reproduzindo resultados promissores em um cenário de "mundo real".

🇧🇷 traduzido
#4

Retrospective Analysis of Incidence and Etiology of Severe Infections in Children Receiving Therapy for High-Risk Neuroblastoma: A Large Single-Center Experience.

Pediatric blood &amp; cancer2026 Mar 15

Este estudo mostra que infecções graves são uma complicação muito comum (56.5% dos pacientes) durante o tratamento de neuroblastoma de alto risco, sendo a maioria infecções na corrente sanguínea. Muitas dessas infecções estão associadas a cateteres venosos centrais, ocorrendo até mesmo em pacientes não neutropênicos, o que ressalta a importância do cuidado rigoroso com esses dispositivos. Embora frequentes, a mortalidade relacionada a essas infecções é muito baixa (1.1%), oferecendo uma perspectiva tranquilizadora para pacientes e seus familiares, ao mesmo tempo que destaca a necessidade de otimizar estratégias de prevenção focadas nos cateteres.

🇧🇷 traduzido
#5

[Correlation study between tumor location and pathological subtypes of neuroblastic tumors associated with opsoclonus myoclonus ataxia syndrome].

Zhonghua er ke za zhi = Chinese journal of pediatrics2026 Mar 14

Objective: To analyze the correlation between the location and pathological subtypes of of neuroblastic tumors (NBT) associated with opsoclonus myoclonus ataxia syndrome (OMAS). Methods: A case-control study. Clinical data of 34 pediatric patients diagnosed with NBT complicated by OMAS (NBT-OMAS group), who were hospitalized in the Department of Pediatrics, Peking University First Hospital from January 2007 and December 2022 were collected retrospectively. The control group consisted of 34 age and sex-matched patients with NBT only (NBT-only group) admitted during the same period. Chi-square test or Fisher exact test was used to compare the distribution of tumor locations and pathological subtypes between the two groups. Cramer's V coefficient was applied to analyze the correlation between them. The outcomes of the patients were followed up. Results: The age of patients in the NBT-OMAS group was 18 (12, 28) months, while that of the NBT-only group was 20 (13, 31) months. In the NBT-OMAS group, 28 cases (82%) had tumors located in the paraspinal sympathetic chain and 6 cases (18%) in the adrenal glands. In the NBT-only group, 6 cases (18%) had tumors located in the adrenal glands and 28 cases (82%) in the paraspinal sympathetic chain, with a statistically significant difference between the two groups (χ2=10.69, P<0.01). The distribution of pathological subtypes of tumors in the NBT-OMAS group was as follows: 20 cases (59%) of ganglioneuroblastoma (GNB), 10 cases (29%) of neuroblastoma (NB), 4 cases (12%) of ganglioneuroma (GN). In the NBT-only group, NB was predominant with 21 cases (62%), GNB in 13 cases (38%), and no GN subtype was observed. There was a statistically significant difference between the two groups (χ2=8.59, P<0.01). In the NBT-OMAS group, the pathological subtype of tumors located in the adrenal gland was mainly NB, with 5 cases (5/6). For tumors located paravertebral to the thoracic and lumbar spine, the predominant subtype was GNB, with 8 cases (8/11) and 11 cases (11/13) respectively. As for tumors paravertebral to the sacral spine, the major subtype was NB, with 3 cases (3/4). In the NBT-only group, NB was the pathological subtype in 18 cases of adrenal gland tumors (18/19). For tumors paravertebral to the cervical spine, NB and GNB each accounted for 2 cases respectively (2/4). Tumors located paravertebral to the thoracic spine and paravertebral to the lumbar spine were all GNB for 5 cases (5/5), while those paravertebral to the sacral spine were all NB for 1 case (1/1). The Cramer's V coefficients of the tumor location and pathological subtype in the two groups were 0.65 and 0.81, respectively. The follow-up ended on December 31, 2023. In the NBT-OMAS group, 1 case had tumor recurrence and 1 case died due to tumor progression; both the recurrent and fatal tumors were located in the adrenal glands with the pathological subtype of NB. In the NBT-only group, 11 cases died of tumor progression, among which 8 cases had primary tumor located in the adrenal gland and with the pathological subtype of NB. Conclusions: In children with NBT-OMAS, tumors located in the paravertebral sympathetic chains are significantly more common than those in the adrenal gland, the pathological subtype of tumors was predominantly GNB. The tumor location was correlated with its pathological subtype. 目的: 分析并发眼阵挛肌阵挛共济失调综合征(OMAS)的神经母细胞肿瘤(NBT)肿瘤发生部位与病理亚型的相关性。 方法: 病例对照研究。收集2007年1月至2022年12月在北京大学第一医院儿科住院且明确诊断为NBT并发OMAS的34例患儿(NBT-OMAS组)临床资料,对照组为同期入院、年龄和性别都匹配的单纯NBT患儿34例(单纯NBT组),采用χ2 检验或Fisher确切概率法比较两组肿瘤发生部位、病理亚型的分布情况,通过Cramer′s V系数比较两者的相关性,随访患儿结局。 结果: NBT-OMAS组患儿年龄18(12,28)月龄,单纯NBT组年龄为20(13,31)月龄。NBT-OMAS组肿瘤发生于脊柱旁交感神经链者28例(82%)、肾上腺者6例(18%);单纯NBT组中发生于肾上腺和脊柱旁交感神经链者分别为19例(56%)和15例(44%),两组比较差异有统计学意义(χ2=10.69,P<0.01)。NBT-OMAS组肿瘤病理亚型分布为节细胞神经母细胞瘤(GNB)20例(59%),神经母细胞瘤(NB)10例(29%),节细胞神经瘤(GN)4例(12%);单纯NBT组病理类型主要为NB 21例(62%),GNB 13例(38%),无GN亚型,两组比较差异有统计学意义(χ2=8.59,P<0.01)。NBT-OMAS组中,6例肿瘤位于肾上腺者中5例为NB;11例位于胸椎旁者中8例为GNB;13例位于腰椎旁者中11例为GNB;4例位于骶椎旁者中3例为NB。单纯NBT组中,19例肿瘤位于肾上腺中18例为NB;4例位于颈椎旁者中NB和GNB各占2例;5例位于胸椎旁和5例位于腰椎旁者均为GNB;1例位于骶椎旁者为NB。两组肿瘤所在部位与其病理亚型的Cramer′s V系数分别为0.65、0.81。随访截至2023年12月31日,NBT-OMAS组1例肿瘤复发、1例因肿瘤进展死亡,肿瘤均位于肾上腺且病理亚型为NB;单纯NBT组有11例因肿瘤进展死亡,其中8例原发肿瘤位于肾上腺且病理亚型为NB。 结论: NBT-OMAS患儿肿瘤发生于脊柱旁交感神经链者明显多于肾上腺者;肿瘤病理亚型以GNB者为主;肿瘤发生部位与其病理亚型相关。.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC23.061 artigos no totalmostrando 198

2026

Engineering high-fidelity tapasin variants to enhance MHC-I antigen presentation.

The Journal of biological chemistry
2026

Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia.

The Turkish journal of pediatrics
2026

Involvement of 75NTR extracellular domain in rotenone-induced Parkinson's disease cell models.

Neuroreport
2026

Metabolomics-guided identification of bioactive phytometabolites from South African plants targeting neuroblastoma.

Experimental biology and medicine (Maywood, N.J.)
2026

MicroRNA combinations function as synergistic network regulators of neuroblastoma differentiation.

bioRxiv : the preprint server for biology
2026

Case Report: Spontaneous Tumor Lysis Syndrome in a Patient With Cholangiocarcinoma.

Journal of investigative medicine high impact case reports
2026

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1.

British journal of cancer
2026

Feruloyl substitution is associated with distinct neurogenic and metabolic signatures in cinnamoylquinic acid derivatives: An integrated transcriptomic-metabolomic analysis.

Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie
2026

Arsenic Promotes Intracellular Aβ(1-42) Accumulation via Enhanced APP but Reduced NEP Expression, and Indirectly Stimulates Extracellular Aβ Aggregation through AChE Induction in Differentiated SH-SY5Y Cells.

Biological trace element research
2026

BCL-2 Mediated Apoptotic Pathway as Promising Target for Bio- Synthesized Silver Nanoparticles: A Review Article.

Current medicinal chemistry
2026

Unveiling a novel NBAS mutation in common variable immunodeficiency: Expanding the genetic landscape of immunodeficiency disorders.

Immunobiology
2026

LMO1 expression in neuroblastoma cells reprograms tumor-associated macrophages to promote metastasis.

iScience
2026

Telomere maintenance mechanisms are activated in ganglioneuroblastoma and ganglioneuroma.

Oncology letters
2026

Inhibition of USP7 destabilizes the noncanonical PRC1.1 complex and induces neuroblastoma differentiation.

Molecular cancer research : MCR
2026

Simplified dosimetry using two-time-point kinetic modeling of 124I-MIBG PET for 131I-MIBG therapy in neuroblastoma.

Medical physics
2026

The Excelsatoxin A-Receptor TMEM233 Modulates Nav1.8.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Therapy-related acute myeloid leukemia following successful treatment of high-risk neuroblastoma in a pediatric patient: a case report and insights into late complications.

Frontiers in oncology
2026

Neuroprotective potential of a novel marine metabolite from S. rhizophila BGNAK1 targeting acetylcholinesterase in Alzheimer's disease.

3 Biotech
2026

Radiofrequency exposure to LTE signal does not alter cancer-related endpoints in human neuroblastoma cell model either alone, or co-exposed to menadione or Wi-Fi signal.

Environmental research
2026

A case report of pediatric robotic adrenalectomy: pushing boundaries on the robotic platform.

Journal of minimally invasive surgery
2026

Synthesis, Radiochemical Characterization, and Biodistribution of a 188Re Analogue of [131I]mIBG in a Neuroblastoma Xenograft Model.

Journal of labelled compounds &amp; radiopharmaceuticals
2026

A CDCA2-MYC positive feedback loop controls cancer cells survival.

Open biology
2026

Beta-Amyloid Suppresses Mitochondrial ATP Production in Human Neuroblastoma Cells.

Biochemistry. Biokhimiia
2026

Expression of Concern: Ezrin interacts with the tumor suppressor CHL1 and promotes neuronal differentiation of human neuroblastoma.

PloS one
2026

Simultaneous inhibition of mTOR and STING as an approach to reduce alpha-synuclein and lysosphingolipid levels in peripheral blood monocytederived macrophages and the SH-SY5Y cell line: implications for therapy of Parkinson's disease.

Biomeditsinskaia khimiia
2026

Paraneoplastic Lupus Nephritis in a Child With Neuroblastoma Recurrence.

Pediatric blood &amp; cancer
2026

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience.

Pediatric blood &amp; cancer
2026

GPC2 provides prognostic value in pan-pediatric cancers and is associated with MYCN amplification in neuroblastoma: bioinformatics analysis and validation.

BMC cancer
2026

Milk-derived miR-126-3p-loaded small extracellular vesicles attenuate amyloid-β-induced cellular stress in a neuroblastoma cell model.

BMC neuroscience
2026

Integrating next-generation sequencing into the routine neuroblastoma workflow identifies actionable genomic alterations and reduces low-yield karyotype testing.

Virchows Archiv : an international journal of pathology
2026

Extracellular amyloid-β42 oligomers alter endo-lysosomal trafficking of Rab7- and Lamp-1-coated vesicles in cultured neuroblastoma cells.

Journal of Alzheimer's disease : JAD
2026

Characterization of intestinal immune responses in generalized human and murine lipodystrophy.

The Journal of clinical investigation
2026

Inhibition of CDK1 Promotes Immunogenic Cell Death in Neuroblastoma.

Cancer management and research
2026

Airway Obstruction as the First Clue: Syndromic Neurocristopathy With Neuroblastoma, Hirschsprung Disease, and PHOX2B Mutation in a Neonate.

Pediatric blood &amp; cancer
2026

Retrospective Analysis of Incidence and Etiology of Severe Infections in Children Receiving Therapy for High-Risk Neuroblastoma: A Large Single-Center Experience.

Pediatric blood &amp; cancer
2026

A Case of Pediatric Adrenocortical Carcinoma With McCune-Albright Syndrome Masquerading as Spontaneously Regressing Neuroblastoma.

Pediatric blood &amp; cancer
2026

[Correlation study between tumor location and pathological subtypes of neuroblastic tumors associated with opsoclonus myoclonus ataxia syndrome].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2026

Understanding the Burden of Care for Children With Pediatric Solid Tumors.

Pediatric blood &amp; cancer
2026

Cyclosporine Resolved Late Graft Failure After Autologous Transplantation for Neuroblastoma by Promoting CD4 T-Cell Recovery.

Pediatric blood &amp; cancer
2026

Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors.

Pediatric blood &amp; cancer
2026

Sarsasapogenin ameliorates Alzheimer's disease by dual inhibition of RIPK1-mediated necroptosis and pyroptosis.

Cellular signalling
2026

Bortezomib Induces Apoptosis via Upregulation of Abhd4 in Peripheral Nerve Cells.

Biological &amp; pharmaceutical bulletin
2026

Molecular Insights of Neuroprotective Effect of Cornulaca monacantha Extract Against LPS-Induced Neuroinflammation Supported by Metabolic Profiling and Protein Interaction Analysis.

International journal of molecular sciences
2026

Estetrol Enhances Mitochondrial Bioenergetics and Neurite Outgrowth in Cellular Models of Alzheimer's Disease.

Cells
2026

Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies.

Cells
2026

4-Methoxydalbergione Induces Dual Activation of Apoptosis and Autophagy-Dependent Cell Death via ROS-MAPK Signaling in Human Neuroblastoma Cells.

Cells
2026

A Novel Competing Endogenous RNA Linked to Dysregulated Neuroinflammation in Alzheimer's Disease.

Cells
2026

Geniposide ameliorates ferroptosis through the ROS/p38 MAPK/NCOA4/GPX4-mediated ferritinophagy in a co-culture system of HMC3 and SH-SY5Y cells.

Neurotoxicology
2026

Bilateral blindness from optic chiasm metastasis as the initial presentation of stage 4 neuroblastoma: A case report.

Medicine
2026

Distinct Clinical Significance of Minimal Residual Disease Detected by 7NB-mRNAs Expression in Bone Marrow at Different Time Points of High-Risk Neuroblastoma Patients.

Biology
2026

Unveiling the molecular landscape: Long non-coding RNAs in neuroblastoma (Review).

Oncology reports
2026

Imaging of High-Risk Neuroblastoma: Recommendations From SIOPEN Radiology and Nuclear Medicine Specialty Committees.

Pediatric blood &amp; cancer
2026

Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study.

Pediatric blood &amp; cancer
2026

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study.

Pediatric blood &amp; cancer
2026

Determination of the effects of Herpes simplex glycoprotein B on epigenetic alterations in in vitro models of Alzheimer's disease.

Journal of Alzheimer's disease : JAD
2026

Black Currant Extract Protects against Oxidative Stress in SH-SY5Y Cells and High-Fat Diet-Induced Cognitive Impairment in C57BL/6 Mice.

Journal of microbiology and biotechnology
2026

Laparoscopic Adrenal Compartment Resection for Paediatric Adrenal Neoplasms: Surgical Technique and Single-Centre Experience.

European journal of haematology
2026

Risk of neuroblastoma among patients with pediatric Horner syndrome.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
2026

Effect of MYCN Amplification on Tumor Response and Recurrence in Patients With Stage IV Neuroblastoma.

JCO precision oncology
2026

Giant cervical lipoblastoma in infant: a rare case report.

International journal of surgery case reports
2026

Engineered Peptide Coassembly Enables Precision Delivery of As(III)-Peptide Complexes and Counteracts Inflammation-Dependent Therapeutic Resistance in High-Risk Neuroblastoma.

ACS nano
2026

The roles and pathways of Hsa_circ_0000285 in cancer: a potential target for cancer therapy.

Cell division
2026

Extracellular vesicles released in vitro from a Parkinson's disease-like model: a combined biochemical and spectroscopic approach as proof of concept for the diagnosis of neurodegenerative diseases.

Analytica chimica acta
2026

Nanotip acetylcholine biosensor reveals cholinergic differentiated SH-SY5Y cells release partial vesicle content during exocytosis.

Bioelectrochemistry (Amsterdam, Netherlands)
2026

Role of human RNase 7 in neuronal and glial cell models: moving towards an unexpected new functional link.

The FEBS journal
2026

Fatty acid transporter protein isoform 2 (FATP2) inhibitor lipofermata inhibits Zika virus replication and blocks fatty acid uptake in SH-SY5Y neuroblastoma cell line.

Microbiology spectrum
2026

Comparing muscle mass in children with high-risk neuroblastoma using magnetic resonance imaging and bioelectrical impedance analysis.

Translational pediatrics
2026

TFAP2D drives neuroblastoma progression: a disulfidptosis-fatty acid metabolism-based molecular subtyping and prognostic model.

Translational pediatrics
2026

Surgical Management of Esthesioneuroblastoma at a Single Tertiary Care Center.

Journal of neurological surgery. Part B, Skull base
2026

Near-infrared photobiomodulation can alleviate chemotherapy-induced peripheral neuropathy-associated sensory abnormalities.

Journal of photochemistry and photobiology. B, Biology
2026

Acetylated Nanoformulation of N-(4-Hydroxyphenyl)-4-Oxoretinamide Inhibits EZH2-Mediated Epigenetic Repression in Neuroblastoma.

Small (Weinheim an der Bergstrasse, Germany)
2026

Requalification and Data Management of Pediatric Biological Samples Collected since 1984: A Case Study from a Neuroblastoma Collection.

Biopreservation and biobanking
2026

Hesperidin Attenuates H₂O₂-Induced Neurotoxicity via Modulation of Inflammatory Pathways and MMP Activity in Differentiated SH-SY5Y Cells: In Vitro and In Silico Models.

Journal of biochemical and molecular toxicology
2026

Gomisin B promotes RSL3-induced ferroptosis in neuroblastoma by inhibiting the ESR1/USP7/SREBF1 axis.

Cell biology and toxicology
2026

SMARCA4-deficient carcinoma of the head and neck region: report of 8 new sinonasal and non-sinonasal cases and literature review.

Virchows Archiv : an international journal of pathology
2026

Ribosomal modifications are associated with mesenchymal fate selection in the neural crest lineage.

Nature communications
2026

Proton Beam Therapy Versus Photon Radiotherapy for Pediatric Neuroblastoma: A Systematic Review and Meta-Analysis (TRP-2025 Neuroblastoma).

Cancer medicine
2026

3,5-Dibromo-4-hydroxybenzaldehyde induced neurodevelopmental defects via endoplasmic reticulum stress-mediated apoptotic pathway in zebrafish.

Chemico-biological interactions
2026

Microbiota metabolite lithocholic acid in cancer: Mechanisms and therapeutic potential.

Experimental cell research
2026

Virtual Screening and MD Simulation-Driven Discovery of USP7 Inhibitors BML-284.

ACS omega
2026

Upper Gastrointestinal Bleeding Due to Ruptured Gastric Varices: A Diagnostic Challenge.

Cureus
2026

First Case of Neuroblastoma-Like Somatic-Type Malignancy Arising in the Teratomatous Component of a Mixed Non-Seminomatous Testicular Germ Cell Tumor in an Adult.

Clinical case reports
2025

Role of miRNA in diagnosis of Wilms tumor and neuroblastoma.

Indian journal of cancer
2025

The evolving burden of pediatric solid tumors: A global analysis from 1990 to 2021.

Indian journal of cancer
2026

Food-grade TiO2/TDCPP Co-exposure disrupts ACOD1/itaconate axis and is associated with TET2-NF-κB inflammation in microglia exacerbating neurotoxicity.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
2026

Reframing disease burden: validation of DALY-per-case as a per-diagnosis severity metric.

Population health metrics
2026

Upregulation of TRPV2 exacerbates age-related hearing loss by promoting oxidative stress in spiral ganglion neurons.

Molecular brain
2026

Analyzing Nicotine Action Against Amyloid Toxicity by NMR-Pharmacometabolomics: An Exploratory Study.

NMR in biomedicine
2026

Rethinking the Role of Contrast-enhanced MRI in Pediatric Neuroblastoma: From Image-defined Risk Factors to Intratumoral Heterogeneity.

Radiology. Imaging cancer
2026

KDM5D expression is lost in cisplatin‑resistant neuroblastoma cells.

Oncology reports
2026

In vitro studies to investigate the potential neuroprotective and neurotransmitter modulation effects of a standardized Ginkgo biloba extract associated with phosphatidylserine.

Frontiers in nutrition
2026

Spatial analysis of residential location at birth, PFAS in public water, and childhood cancers in Southern California (2000-2019).

Journal of exposure science &amp; environmental epidemiology
2026

Pituitary dysfunction in childhood after [177Lu]Lu-DOTATATE therapy.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Potential Therapeutic Targets for Neuroblastoma Screened through Mendelian Randomization Analysis.

Archives of Iranian medicine
2026

Identification and validation of an endoplasmic reticulum stress related model to predict prognosis and tumor microenvironment in neuroblastoma.

BMC cancer
2026

Integrative Genomic Profiling of Pediatric Solid Tumors Reveals Clinically Relevant Variants and Chromosomal Arm Aneuploidies Signatures.

Cancer medicine
2026

Maternally Expressed Gene 3 (MEG3) LncRNA: The silent guardian against solid and hematological malignancies.

Critical reviews in oncology/hematology
2026

Solitary Humeral Metastasis in the Absence of Detectable Primary Neuroblastoma on Triple-tracer Imaging With 18F-FDG, 123I-MIBG, and 68Ga-DOTATATE.

Clinical nuclear medicine
2026

Collecting Social Determinants of Health in a Children's Oncology Group Trial for High-Risk Neuroblastoma.

JAMA network open
2026

CAR-T cell therapy for pediatric solid tumors: armored CAR-T cells and beyond.

Cancer metastasis reviews
2026

Bronchiolitis Obliterans Syndrome Following High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in a Pediatric Patient With Neuroblastoma.

Cureus
2026

Neurotoxicity of mancozeb-based commercial fungicide in human neuroblastoma SH-SY5Y cells.

EXCLI journal
2026

DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma.

Cancer letters
2026

DNMT3A R882C variant in a patient with a presumed pineal gland tumor, highlighting potential tumor susceptibility in Tatton-Brown-Rahman syndrome.

Cancer genetics
2026

Congenital cervical neuroblastoma presenting with spontaneous tumour lysis syndrome and severe neonatal airway compromise.

BMJ case reports
2026

CAR-NKT cell therapy for tumors: promise and progress.

Pathobiology : journal of immunopathology, molecular and cellular biology
2026

A novel GMP-manufactured medicinal product candidate composed of NK and γδ T cells as adjunct immunotherapy for hematopoietic stem cell transplantation.

Cell transplantation
2026

Repetitive Magnetic Stimulation Modulates the Gene Expression of Neurotrophins and their Receptors in Neuroblastoma Cells.

Anticancer research
2026

Bilateral proptosis as the first manifestation in a patient with acute myeloid leukemia: Case report.

Medicine
2026

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.

bioRxiv : the preprint server for biology
2026

Enhanced cytotoxic activity of Moringa oleifera-loaded pharmacosomes against neuroblastoma.

Nanoscale advances
2026

miR-137-5p-Loaded Milk-Derived Small Extracellular Vesicles Modulate Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammatory Responses in an In Vitro Alzheimer's Disease Model.

Pharmaceutics
2026

Enhancement of Cytoskeletal Tension Promotes Amyloid-β Aggregation on the Neuronal Cell Surface.

Molecules (Basel, Switzerland)
2026

GD2-Targeted Minibody-Drug Conjugates Match the Potency of IgG-Based ADCs in a Mouse Cancer Model.

International journal of molecular sciences
2026

Jurkat T-Cell Antigen-Independent Elimination of PMA-Activated Neuroblastoma Cells Is Triggered by CCL2/CCR2, Depends Upon Lipid Raft LFA1/ICAM1 Immune Synapses, Is Mediated by m-TRAIL and Is Augmented by the TrkAIII Oncoprotein.

International journal of molecular sciences
2026

In Vitro Anticancer Activity and In Silico Target Profiling of 5-(Piperazin-1-ylsulfonyl)-1,3-oxazole-4-carbonitriles.

International journal of molecular sciences
2026

Discovery of New Antioxidant Molecules Enhancing the Nrf2-Mediated Pathway: Docking Studies and Biological Evaluation.

International journal of molecular sciences
2026

Differential Gene Expression in Differentiated Human Neuroblastoma SH-SY5Y Cells in Response to a Cocktail of Monoamine Oxidase Inhibitors.

International journal of molecular sciences
2026

Design and Synthesis of Caffeine-Based Derivatives with Antioxidant and Neuroprotective Activity: In Vitro Evaluation and SwissADME Profiling.

Antioxidants (Basel, Switzerland)
2026

Lipid Peroxidation Products 4-ONE and 4-HNE Modulate Voltage-Gated Sodium Channels in Neuronal Cell Lines and DRG Action Potentials.

Antioxidants (Basel, Switzerland)
2026

Exosomes as Specific Vehicles for Delivery of Combination Therapies for Inhibiting Autophagy and Inducing Apoptosis in MYCN-Amplified Neuroblastoma Displaying Gut Dysbiosis: Current Challenges and Future Opportunities.

Brain sciences
2026

Neuroblastoma by Stage at Diagnosis and Other Prognostic Factors: The Results of the BENCHISTA Italian Project-A Population-Based Study.

Cancers
2026

Neuroblastoma Presenting as a Congenital Renal Mass in a Neonate: A Diagnostic Pitfall.

Children (Basel, Switzerland)
2026

Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Neuroblastoma.

Children (Basel, Switzerland)
2026

Established and Emerging Therapies for High-Risk Neuroblastoma.

Paediatric drugs
2026

Eurycomanone from Eurycoma longifolia Jack roots regulates dopamine secretion via transsynaptic GABA signalling in differentiated SH-SY5Y human neuroblastoma cells: a transcriptomic study.

Molecular biology reports
2026

Loss of HuD Sensitizes Neuroblastoma Cells to Palmitate-Driven Stress-Induced Premature Senescence via PPARα Downregulation and FAO Impairment.

Cells
2026

Primary CNS Neuroblastoma, FOXR2-Activated: Clinicopathological Study of Two Cases With Immunohistochemical Characterization and Literature Review.

Neuropathology : official journal of the Japanese Society of Neuropathology
2026

Jumonji domain-containing 6 promotes the expansion of neuroblastoma stem cells by activating the wingless/ integrated pathway.

CytoJournal
2026

Erastin-induced ferroptosis enhances natural killer cell anti-tumor activity and offers therapeutic potential in neuroblastoma.

Frontiers in immunology
2026

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.

Cell death &amp; disease
2026

Comparison of late dental sequelae in survivors of high-risk neuroblastoma treated with myeloablative high-dose chemotherapy and peripheral blood stem cell transplantation.

Oral surgery, oral medicine, oral pathology and oral radiology
2026

Inhibiting AP2M1-mediated GluA2 endocytosis by G2CT peptide ameliorates synaptic and memory deficits in Alzheimer's Disease.

Neuropharmacology
2026

Multiplexed biomarkers dynamically detect heterogeneous residual neuroblastoma cell clone activity in the bone marrow niche.

Cancer letters
2026

Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China.

Frontiers in oncology
2026

Environmental Mycotoxins and Brain Health: Protective Role of Bromelain Against Fumonisin B1 in SH-SY5Y Cells.

Environmental toxicology
2026

Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma.

Thyroid : official journal of the American Thyroid Association
2026

Development and validation of a clinico-histological factor-based nomogram for survival in sinonasal malignancies.

Scientific reports
2026

25-nitro-20-epi-vitamin D analogue with anti-proliferative and cytoprotective properties: Biological and pharmacological evaluation.

Experimental and molecular pathology
2026

Human herpesvirus 6 and non-human herpesvirus 6 limbic encephalitis in children with allogeneic stem cell transplantation: A case series.

Brain &amp; development
2026

Identification of potential clinical markers associated with prognosis of neuroblastoma.

Discover oncology
2026

Prognostic Value of a Semi-Quantitative Score Based on 123I-MIBG SPECT/CT in Pediatric Patients With Stage 4 High-Risk Neuroblastoma After Induction Therapy.

Clinical nuclear medicine
2026

Autologous Stem Cell Transplantation for High-Risk Neuroblastoma - A Real-World Evidence from A Tertiary Cancer Care Center in Southern India.

Indian journal of hematology &amp; blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
2026

Investigating Microtubule-Associated Protein 2 in the Study of Postoperative Delirium.

Delirium (Bielefeld, Germany)
2026

Oleic Acid-Coated Zinc Ferrite Nanocubes: A Promising Nanocarrier for Neuroblastoma Therapy.

ACS omega
2025

Synchronous malignant rhabdoid tumor of the kidney and adrenal neuroblastoma in an infant treated with proton beam therapy: a case report and literature review.

Frontiers in oncology
2026

Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma.

Clinical and translational science
2026

Alternative Translation Initiation in PRKN Delays the Onset of Parkinson's Disease and Offers a Therapeutic Target.

Annals of neurology
2026

Can indocyanine green fluorescence aid operative decision making in neuroblastic tumour surgery? Early experience from a single centre.

Journal of pediatric surgery
2026

Alpha-synuclein overexpression triggers divergent cellular responses and post-translational modifications in SH-SY5Y and ReNcell VM models.

Cellular and molecular life sciences : CMLS
2026

Targeted HDAC8 inhibition with non-hydroxamate [1,2,4]triazolo[4,3-a] quinoline compounds.

Scientific reports
2026

Loss of function variants in HPDL impair human cortical development via alterations of mitochondrial function.

Cell death &amp; disease
2026

REFCOR guidelines for sinus and nasal cavity cancer.

European annals of otorhinolaryngology, head and neck diseases
2026

Successful Multimodal Treatment of SMARCA4-Deficient Sinonasal Carcinoma.

Ear, nose, &amp; throat journal
2026

Precision Pediatric Cancer Nanomedicine: Advancing Personalized Nano Therapies to Reduce Non-Communicable Diseases Through AI-Driven 3D-Printed Drugs.

International journal of nanomedicine
2026

Differential inclusion formation of an aggregation-prone protein reveals differences in the proteostasis capacity of neuronal cell lines.

Biochimica et biophysica acta. Molecular cell research
2026

The immunosuppressive role of HLA-G+ extracellular vesicles in bone marrow of infiltrating tumors: the lesson learned from neuroblastoma and multiple myeloma.

Human immunology
2026

Naxitamab for Relapsed/Refractory Neuroblastoma.

Journal of pediatric hematology/oncology nursing
2026

Sensitive and rapid DPV detection of urinary homovanillic acid via g-C3N4@nZVI modified carbon paste sensor.

RSC advances
2026

Breast masses in childhood: a single-center experience.

Frontiers in pediatrics
2026

The Prognostic Value of MIBG Metastatic Patterns in Pediatric Patients with High-Risk Stage 4 Neuroblastoma Following Induction Therapy.

Academic radiology
2026

Taxonomic characterization and toxicity assessment of strains of Gambierdiscus belizeanus from Seychelles, southwestern Indian Ocean.

Harmful algae
2026

The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma.

The Journal of biological chemistry
2026

4-MEC potentially triggers CAV1 via the BDNF-TrkB signaling pathway.

Molecular and cellular neurosciences
2026

Synthetic cannabidiol analogues exhibit lower toxicity than cannabidiol and protect against ethanol-induced apoptosis in SH-SY5Y cells.

Neurotoxicology
2026

Evaluation of Long-Term Late Side Effects in High-Risk Neuroblastoma Patients Undergoing Autologous Bone Marrow Transplantation.

Klinische Padiatrie
2026

Dinutuximab-Associated Neurotoxicity: Incidence, Presentation, Risk Factors, and Nursing Interventions.

Journal of pediatric hematology/oncology nursing
2026

Betaine alleviates neuronal impairment in glutamate-injured SH-SY5Y neuroblastoma cells via Nrf2 signaling pathway related ferroptosis.

Journal of neuroimmunology
2026

GD2-directed NAMPT inhibition using antibody-drug conjugates in neuroblastoma.

European journal of medicinal chemistry
2026

H3K27ac-Activated lncRNA-DAPK1-IT1 Aggravated Oxidative Stress Damage Induced by Focal Cerebral Ischemia/Reperfusion via the miR-25-3p/HMGB1 Molecular Axis.

Molecular neurobiology
2026

Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression.

Cancer biology &amp; medicine
2026

Early Detection of Neuroblastoma Recurrence on 18F mFBG PET.

Clinical nuclear medicine
2026

Multifactorial Neuroprotective Potential of γ-Aminobutyric acid-Producing Potential Probiotics Against Stress Induced Neuronal Cell Lines.

Probiotics and antimicrobial proteins
2026

The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing.

Frontiers in immunology
2026

Implications of Fatty Acid Metabolism Genes on the Prognostic Landscape of Neuroblastoma: Integration of Genetic and Immune Profiles.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
2026

Probing the influence of low-level laser therapy on cellular and standard proteins by light emitting diode -induced autofluorescence spectroscopy.

Journal of photochemistry and photobiology. B, Biology
2026

Multiple endocrine neoplasia type 5: emerging evidence and clinical perspectives.

Endocrine-related cancer
2026

Persicaria hydropiper attenuates oxidative stress and reactive oxygen species, and inhibits amyloid-β/tau in SH-SY5Y cell lines via multiple pathways of Alzheimer's disease.

Journal of Alzheimer's disease : JAD
2026

First Clinical Application of Repeated Boron Neutron Capture Therapy for Olfactory Neuroblastoma: Achieving Local Control Despite Regional Progression.

Cureus
2026

Subcytotoxic Exposure to Avobenzone and Ethylhexyl Salicylate Induces microRNA Modulation and Stress-Responsive PI3K/AKT and MAPK Signaling in Differentiated SH-SY5Y Cells.

International journal of molecular sciences
2026

Neuroblastoma in Childhood: Biological Insights, Risk Stratification, and Advances in Multimodal Therapy.

Journal of clinical medicine
2026

Characterization of Clinical Outcomes for Patients with Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplant and External Beam Radiotherapy.

Cancers
2026

Detection and Characterisation of Circulating Tumour Cell Clusters in Neuroblastoma.

Cancers
2026

YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells.

Cancers
2026

Orthopedic manifestations as presenting symptoms in children with neuroblastoma: a retrospective case series and clinical review.

Journal of orthopaedic surgery and research
2026

Acetyl-11-keto-β-boswellic acid attenuates tau oligomer-induced neurotoxicity in neuroblastoma cell model.

BMC neuroscience
2026

Gender Equity in pediatric surgical care in Central and South Asia: A systematic review and meta-analysis.

Journal of pediatric surgery
2026

Circadian rhythm heterogeneity modulates drug response variations in neuroblastoma models.

Cell reports
2026

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

The Journal of clinical investigation
2026

Histotripsy-initiated immune response synergizes with chemotherapy in a neuroblastoma murine model.

bioRxiv : the preprint server for biology
2026

Quantifying Mechanical Strain-Induced Membrane Damage in Early Neuronal Cells Using an In Vitro Traumatic Brain Injury Model.

Bio-protocol
2026

NeuroD1-USP1-MYCN axis drives tumor progression in neuroblastoma.

Journal of translational medicine
2026

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

International journal of cancer
2026

Spatially Resolved Sequential Activation of Allosteric DNA for In Vivo Dual-Target Detection within Mitochondria: A Strategy to Visualize of Drug-Resistant Neuroblastoma.

ACS sensors
2026

Therapeutic targeting of cancer stem cell-specific surface glycans and glycoproteins.

Discover oncology
2026

O-GlcNAcylation expression predicts a favorable prognosis and mitigates malignant phenotypes via MYCN suppression in neuroblastoma.

Molecular and cellular pediatrics
2026

Med13 is involved in the radial migration and contralateral projection of cortical neurons via PlxnA4.

Communications biology
2026

Neuroprotective and antioxidant properties of Polygala virgata fractions in a 6-hydroxydopamine-induced neurotoxicity model.

Journal of ethnopharmacology
Ver todos os 23.061 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Neuroblastoma.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Neuroblastoma

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia.
    The Turkish journal of pediatrics· 2026· PMID 41871563mais citado
  2. LMO1 expression in neuroblastoma cells reprograms tumor-associated macrophages to promote metastasis.
    iScience· 2026· PMID 41858882mais citado
  3. The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience.
    Pediatric blood &amp; cancer· 2026· PMID 41840813mais citado
  4. Retrospective Analysis of Incidence and Etiology of Severe Infections in Children Receiving Therapy for High-Risk Neuroblastoma: A Large Single-Center Experience.
    Pediatric blood &amp; cancer· 2026· PMID 41834334mais citado
  5. [Correlation study between tumor location and pathological subtypes of neuroblastic tumors associated with opsoclonus myoclonus ataxia syndrome].
    Zhonghua er ke za zhi = Chinese journal of pediatrics· 2026· PMID 41834205mais citado
  6. Targeting LY6E Inhibits Neuroblastoma Progression and Suppresses M2 Macrophage Polarization.
    Hum Mutat· 2026· PMID 41993132recente
  7. Therapeutically relevant rimonabant exposure drives epigenetic remodeling in neuronal cells and rat brain tissue.
    Arch Toxicol· 2026· PMID 41991728recente
  8. The Paracrine TAC1-TACR1 Signaling Promotes Endothelial Senescence and Metastatic Progression in Neuroblastoma.
    Cancer Lett· 2026· PMID 41985871recente
  9. L-BMAA induces neurotoxicity through AMPK/Akt-TSC1/2-mTOR-mediated mitophagy dysregulation and apoptosis.
    J Hazard Mater· 2026· PMID 41985289recente
  10. Genetic association analysis of lnc-AMFR-1:1 rs4784659 C > T and neuroblastoma susceptibility in Chinese pediatric patients.
    Pediatr Surg Int· 2026· PMID 41984207recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:635(Orphanet)
  2. MONDO:0005072(MONDO)
  3. GARD:7185(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q938205(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Neuroblastoma
Compêndio · Raras BR

Neuroblastoma

ORPHA:635 · MONDO:0005072
Prevalência
1-5 / 10 000
Herança
Not applicable
CID-10
C74.9 · Neoplasia maligna da glândula supra-renal, não especificada
CID-11
Ensaios
36 ativos
Início
Adolescent, Antenatal, Childhood, Infancy, Neonatal
Prevalência
11.0 (Europe)
MedGen
UMLS
C0027819
Repurposing
2 candidatos
cyclophosphamideDNA alkylating agent
iobenguaneantineoplastic agent
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades